Largest generic drug company may join PhRMA

John Gregory | | Health Exec | Policy & Regulations

The trade association for brand-name drug manufacturers could soon count the largest generic drug maker among its members—and the brand-name companies aren’t entirely comfortable with the idea.

Teva has requested to join the Pharmaceutical Research and Manufacturers of America (PhRMA), with a decision expected from the PhRMA board later this month.

For more on why brand-name manufacturers like AbbVie say PhRMA would be “diluted” by allowing Teva to join its ranks, click on the link below: 

Brand-Name Drug Makers Wary of Letting Generic Rival Join Their Club

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Related Content

Report: 44% of adults in the U.S. are uninsured or underinsured
Texas AG sues hospital for $10K after off-duty police barred from carrying guns
Cardiologists reflect on developing primary PCI in face of criticism and pushback
PBMs sue FTC for alleged Fifth Amendment violation
FDA issues Class I alert on Philips ventilators after 4 injuries
Trump selects Emmy-winning TV personality Dr. Oz to head CMS

Around the web

Cardiovascular Business
Q&A: MedAxiom CEO explores key trends in cardiologist, cardiovascular surgeon compensation

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

Cardiovascular Business
Payment cuts and beyond: Key takeaways for cardiologists from the 2025 Medicare Physician Fee Schedule

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

AI in Healthcare
A modest proposal to rally AI regulators around a simple game plan

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”